Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gmo Product PlatformTSE:3695 +1.34%71 Debt-to-EBITDA is 0.44 as of Mar. 2026, which is 780% above its 10-year median of 0.05. GuruFocus rates TSE:3695 with a GF Score™ of 71/100 and a GF Value™ of 円1,724.34 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,731 Software companies, Gmo Product Platform ranks worse than 51.36% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Gmo Product Platform's Debt-to-EBITDA or its related term are showing as below:
TSE:3695'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 1.52
Current: 1.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of Gmo Product Platform was 1.52. The lowest was 0.02. And the median was 0.05.
TSE:3695's Debt-to-EBITDA is ranked worse than 51.36% of 1731
companies
in the Software industry
Industry Median: 0.99
vs TSE:3695: 1.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Gmo Product Platform Debt-to-EBITDA Related Terms
Gmo Product Platform Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Gmo Product Platform's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3695 vs MSFT, ORCL, PLTR: Debt-to-EBITDA Comparison
For the Software - Infrastructure subindustry, Gmo Product Platform's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gmo Product Platform Debt-to-EBITDA vs Software Industry
For the Software industry and Technology sector, Gmo Product Platform's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gmo Product Platform's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Gmo Product Platform (TSE:3695) has a Debt-to-EBITDA of 0.44 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gmo Product Platform. This is 780% above median its historical median of 0.05. Over the past decade, Gmo Product Platform's Debt-to-EBITDA has ranged from 0.02 to 1.52. According to the industry distribution chart, Gmo Product Platform ranks #889 out of 1731 companies in the Software industry, placing it in the top 51.4%.
Is Gmo Product Platform's Debt-to-EBITDA too high?
Gmo Product Platform's current Debt-to-EBITDA of 0.44 is 780% above median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.52. The Software industry median Debt-to-EBITDA is 0.99. Gmo Product Platform's value of 0.44 is 55.6% below this industry median. Based on the distribution chart, Gmo Product Platform ranks #889 out of 1731 companies in the Software industry, which is below the industry midpoint. Overall, Gmo Product Platform has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gmo Product Platform's Debt-to-EBITDA compare to MSFT and ORCL?
According to the Software industry distribution chart, Gmo Product Platform ranks #889 out of 1731 companies for Debt-to-EBITDA. This places Gmo Product Platform in the lower half of its industry. The industry median Debt-to-EBITDA is 0.99. Gmo Product Platform's value of 0.44 is 55.6% below this benchmark. Historically, Gmo Product Platform's own Debt-to-EBITDA has ranged from 0.02 to 1.52 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.99, Gmo Product Platform has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Software company?
The median Debt-to-EBITDA among Software companies is 0.99, based on 1,731 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gmo Product Platform's current Debt-to-EBITDA of 0.44 is 55.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gmo Product Platform. For the Software industry, the median Debt-to-EBITDA is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gmo Product Platform's current Debt-to-EBITDA is 0.44, which is 780% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gmo Product Platform stock overvalued right now?
Based on GuruFocus' analysis, Gmo Product Platform (TSE:3695) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,724.34, compared to a current price of 円1,437.00 — trading 16.7% below its estimated fair value. The current Debt-to-EBITDA is 0.44, which is 780% above median its 10-year median of 0.05 and 55.6% below the Software industry median of 0.99. Gmo Product Platform's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Gmo Product Platform (TSE:3695), the current Debt-to-EBITDA is 0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gmo Product Platform (TSE:3695) Overvalued in 2026?
Based on GuruFocus' analysis, Gmo Product Platform stock appears to be undervalued.
The current stock price of 円1,437.00 is trading 16.7% below its estimated GF Value™ of 円1,724.34.
GuruFocus considers Gmo Product Platform to be Modestly Undervalued.
Key valuation signals for TSE:3695:
Debt-to-EBITDA: 0.44 (780% above median its 10-year median of 0.05)
GF Value™: 円1,724.34 vs. price of 円1,437.00 (16.7% below fair value)
Industry Position: 55.6% below the Software median (#889 of 1731)
No single metric tells the full story. See the TSE:3695 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gmo Product Platform Inc offers online payment and business-to-business payment platform services that help startups, tech companies, and SMEs improve payment processing and operational efficiency. The solutions of the company support various business models with digital payment infrastructure and finance-related services.
71GF Score
Get the complete analysis for TSE:3695
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3695 has been successfully added to your 
